Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ying, CHENG NA
NCT05105464: A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors	Recruiting	1/2	97	RoW	SYHA1815, SYHA1815 tablet	Shanghai Runshi Pharmaceutical Technology Co., Ltd, Jilin Provincial Tumor Hospital	Locally Advanced Unresectable Carcinoma	09/23	09/23
NCT04638491: Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients	Completed	1	32	RoW	Lurbinectedin for injection, PM01183	Luye Pharma Group Ltd.	Advanced Solid Tumor	11/23	11/23

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ying, CHENG NA
NCT05105464: A Study to Investigate the Safety of SYHA1815 in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors	Recruiting	1/2	97	RoW	SYHA1815, SYHA1815 tablet	Shanghai Runshi Pharmaceutical Technology Co., Ltd, Jilin Provincial Tumor Hospital	Locally Advanced Unresectable Carcinoma	09/23	09/23
NCT04638491: Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients	Completed	1	32	RoW	Lurbinectedin for injection, PM01183	Luye Pharma Group Ltd.	Advanced Solid Tumor	11/23	11/23